Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05990738 · ClinicalTrials.gov registry record · Phase 1
DAREON™-9: A Study to Test How Well Different Doses of BI 764532 Are Tolerated by People With Small Cell Lung Cancer When Taken Together With a Single Agent Chemotherapy
A Phase 1 study of Small Cell Lung Carcinoma (SCLC), sponsored by Boehringer Ingelheim.
- Active
- Registry status
- Phase 1
- Development phase
- 69
- Enrollment target
- 14
- Study locations
NCT05990738 is a Phase 1 study of Small Cell Lung Carcinoma (SCLC) that is active but no longer recruiting, run by Boehringer Ingelheim. The registered enrollment target is 69 participants. The trial reports 14 study locations across 4 states.
The verdict
NCT05990738, a Phase 1 study of Small Cell Lung Carcinoma (SCLC), is active but no longer recruiting, sponsored by Boehringer Ingelheim.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 69 participants
- Enrollment target
- 14
- Study locations
Study Summary
This study is open to adults with extensive stage small cell lung cancer. The study is in people with advanced cancer that had previously received platinum-based chemotherapy and are eligible to receive a single agent chemotherapy treatment. The purpose of this study is to find the highest dose of BI 764532 that people can tolerate when taken together with a single agent chemotherapy. BI 764532 is an antibody-like molecule that may help the immune system fight cancer. Participants may continue to take BI 764532 as long as they benefit from treatment and can tolerate it. During this time, participants visit the study site regularly. The visits also depend on the response to the treatment. At the study visits, the doctors check the health of the participants, take necessary laboratory tests, and note any health problems that could have been caused by the study treatment.
Conditions Studied
Interventions
- DRUG Topotecan
- DRUG BI 764532
- DRUG Single agent chemotherapy
Study Locations (14)
Other
- INS Curie - Paris
- HOP Civil - Strasbourg
- Institut Gustave Roussy - Villejuif
- Universitätsklinikum Carl Gustav Carus Dresden - Dresden
- Universitätsklinikum Erlangen - Erlangen
- Thoraxklinik-Heidelberg gGmbH am Universitätsklinikum Heidelberg - Heidelberg
- Universitätsmedizin der Johannes Gutenberg-Universität Mainz - Mainz
- Universitätsklinikum Würzburg AÖR - Würzburg
- Polish Mother's Memorial Hospital - Research Institute - Lodz
- Leicester Royal Infirmary - Leicester
Florida
- Mayo Clinic - Florida - Jacksonville
- University of Miami - Miami
District of Columbia
- MedStar Georgetown University Hospital - Washington D.C.
Virginia
- Virginia Commonwealth University - Richmond
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 69 participants |
| Start Date | 2024-02-14 |
| Est. Completion | 2027-07-30 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05990738
The ClinicalTrials.gov registry entry for NCT05990738 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 69 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Boehringer Ingelheim, which has 515 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Small Cell Lung Carcinoma (SCLC) appearing as the primary indexed condition, and to 3 interventions - of which Topotecan is the first listed.
NCT05990738 reports 14 study locations spanning 4 distinct geographic areas - top geographies include Other, Florida, District of Columbia.
Frequently Asked Questions
What is clinical trial NCT05990738 about?
NCT05990738 is a clinical study titled "DAREON™-9: A Study to Test How Well Different Doses of BI 764532 Are Tolerated by People With Small Cell Lung Cancer When Taken Together With a Single Agent Chemotherapy". This study is open to adults with extensive stage small cell lung cancer. The study is in people with advanced cancer that had previously received platinum-based chemotherapy and are eligible to receive a single agent chemotherapy treatment. The purpose of this study is to find the highest dose of ...
What is the current status of trial NCT05990738?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 69 participants. The study started on 2024-02-14. Estimated completion is 2027-07-30.
What conditions does trial NCT05990738 study?
This clinical trial studies the following conditions: Small Cell Lung Carcinoma (SCLC).
What interventions are being tested in trial NCT05990738?
The interventions under investigation include: Topotecan (DRUG), BI 764532 (DRUG), Single agent chemotherapy (DRUG).
Who is sponsoring clinical trial NCT05990738?
This trial is sponsored by Boehringer Ingelheim, which has 515 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05990738 being conducted?
This trial has 14 study locations across District of Columbia, Florida, Virginia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Small Cell Lung Carcinoma (SCLC)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.